1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters by Title

Showing 1,267 results.

Thumbnail for Real-World Outcomes of Secondary Hemophagocytic Lymphohistiocytosis in B-Cell Versus T/NK-Cell Lymphomas: A Propensity-Matched Study

TCL - 1219

Real-World Outcomes of Secondary Hemophagocytic Lymphohistiocytosis in B-Cell Versus T/NK-Cell Lymphomas: A Propensity-Matched Study

Muzammil Dastagir

Poster Presenter: Muzammil Dastagir

$Thumbnail for Real-World Outcomes of Talquetamab in MonumenTAL-1 Trial-Ineligible Versus Trial-Eligible Patients With Relapsed/Refractory Multiple Myeloma$

MM - 1252

Real-World Outcomes of Talquetamab in MonumenTAL-1 Trial-Ineligible Versus Trial-Eligible Patients With Relapsed/Refractory Multiple Myeloma

Juan Ramirez

Poster Presenter: Juan Ramirez

Thumbnail for Real-World Outcomes With Early Adoption of Imetelstat in Patients With Transfusion-Dependent Myelodysplastic Syndromes (MDS): Insights From a United States (US) Community Oncology Chart Review

MDS - 775

Real-World Outcomes With Early Adoption of Imetelstat in Patients With Transfusion-Dependent Myelodysplastic Syndromes (MDS): Insights From a United States (US) Community Oncology Chart Review

Jessy Thomas

Poster Presenter: Jessy Thomas

Thumbnail for Real-World Overall Survival, Richter's Transformation, and Secondary Primary Malignancy Rates in CLL being treated with Fixed-Duration Venetoclax-Based Therapy vs. Indefinite BTK Inhibitor Monotherapy: A TriNetX Propensity-Matched Analysis

CLL - 1511

Real-World Overall Survival, Richter's Transformation, and Secondary Primary Malignancy Rates in CLL being treated with Fixed-Duration Venetoclax-Based Therapy vs. Indefinite BTK Inhibitor Monotherapy: A TriNetX Propensity-Matched Analysis

Avi Harisingani

Poster Presenter: Avi Harisingani

Thumbnail for Real-World Patient Characteristics, Treatment Patterns, and Blood Counts of Patients With Essential Thrombocythemia Treated With Ropeginterferon Alfa-2b in the US Community Oncology Setting

MPN - 1090

Real-World Patient Characteristics, Treatment Patterns, and Blood Counts of Patients With Essential Thrombocythemia Treated With Ropeginterferon Alfa-2b in the US Community Oncology Setting

Solly Chedid

Poster Presenter: Solly Chedid

Thumbnail for Real-World Pharmacovigilance Assessment of Hematologic Safety Signals Among Bruton Tyrosine Kinase Inhibitors, Including Pirtobrutinib: Insights From the Food and Drug Administration Adverse Event Reporting System

CLL - 179

Real-World Pharmacovigilance Assessment of Hematologic Safety Signals Among Bruton Tyrosine Kinase Inhibitors, Including Pirtobrutinib: Insights From the Food and Drug Administration Adverse Event Reporting System

Klesta Cocoli

Poster Presenter: Klesta Cocoli

Thumbnail for Real-World Phlebotomy (PHL) Burden and Treatment Gaps in US Patients with Polycythemia Vera (PV): A Chart Review Across Physician Practice Settings

MPN - 572

Real-World Phlebotomy (PHL) Burden and Treatment Gaps in US Patients with Polycythemia Vera (PV): A Chart Review Across Physician Practice Settings

Andrew Srisuwananukorn

Poster Presenter: Andrew Srisuwananukorn

Video

Thumbnail for Real-world practice with generic venetoclax and generic Azacitidine in Acute Myelogenous Leukemia (AML) with different risk groups

AML - 643

Real-world practice with generic venetoclax and generic Azacitidine in Acute Myelogenous Leukemia (AML) with different risk groups

Maher Salamoon

Poster Presenter: Maher Salamoon

ABCL - 1583

Real-world propensity score matched outcomes of CAR-T therapy in patients aged =65 years versus 18-64 years with DLBCL

Milan Regmi

Poster Presenter: Milan Regmi